ArticleHealth economics review2025

Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China.

Luwei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.